$2.1 Billion Headline, $1.8 Billion Net: What STERIS's Xodus Deal Teaches Owners
On October 12, STERIS announced a definitive agreement to buy Xodus Medical, a Pennsylvania maker of surgical positioning products, for $2.1 billion at closing. STERIS itself says expected cash tax benefits with a present value of about $300 million bring the net purchase price to roughly $1.8 billion, and it adds an earnout of up to $150 million tied to 2028 results. One deal therefore carries at least three prices, and owners who understand how they fit together are better prepared to read any offer they receive.
What STERIS announced
STERIS Corporation, a subsidiary of STERIS plc (NYSE: STE), will acquire all of the equity of Xodus Medical and certain related affiliates, according to the company's announcement as reported by Stock Titan and Investing.com. Xodus is best known for its Pink Pad patient positioning system, and STERIS says the portfolio adds consumables used in the operating room to its existing offering. The purchase is expected to be funded primarily with debt and to close by December 31, 2026, subject to regulatory approvals and customary conditions.
STERIS projects Xodus will generate about $245 million of revenue in calendar 2026, with adjusted EBIT (earnings before interest and taxes) of about $135 million. That adjusted figure starts from projected operating income of $121 million and adds back roughly $14 million of charges, mostly a royalty arrangement that was terminated during 2026. STERIS CEO Dan Carestio said the business has shown it can grow at double-digit rates. The company did not give a specific growth figure or an earnings-per-share estimate, and it said it will issue a revised fiscal 2027 outlook after closing.
Where a $300 million tax benefit comes from
The announcement does not describe the legal structure, so the source of the tax benefit is not stated. In deals of this kind, however, a common source is a step-up in tax basis. When a buyer purchases assets, or purchases stock in a way the tax code treats as an asset purchase, it can record the assets at the price it paid rather than at the seller's old, lower tax values. The difference, much of it classified as goodwill, can generally be deducted over 15 years under U.S. tax rules. Those deductions reduce the buyer's future tax bills, and the present value of that saving is what STERIS appears to be counting.
The size of the benefit is worth noticing. Roughly $300 million against a $2.1 billion price is about 14% of the closing payment. A buyer that expects to capture that value will often be willing to pay more headline price to get the structure it wants, and a seller who is unaware of it may leave that value on the table.
Three prices in one deal
It helps to separate the figures. The first is the headline price of $2.1 billion at closing, before adjustments. The second is the net price of about $1.8 billion, after the buyer's tax benefits. The third is the maximum price if every earnout target is met, which is $2.25 billion on a headline basis (about $1.95 billion net of the same tax benefit). Using STERIS's own projections, the headline price works out to roughly 8.6 times projected 2026 revenue and 15.6 times adjusted EBIT. On a net basis the multiple of adjusted EBIT falls to about 13.3 times. If the $14 million of add-backs is ignored and the $121 million of operating income is used instead, the multiples are about 17.4 times headline and 14.9 times net. These are our own calculations from the announced figures, and they show how much the answer to "what multiple did they pay" depends on which numbers sit in the numerator and the denominator.
This is why sophisticated buyers talk about effective price. Two offers with the same headline can leave a seller in very different places once tax structure, adjustments, and contingent payments are counted. Owners comparing offers should ask each bidder to show the price on the same basis, ideally after tax to the seller.
What it means if you are the seller
A tax benefit for the buyer often has a cost for the seller, and that cost is the negotiating point. A seller that holds C corporation stock, for example, may face a second layer of tax if the buyer insists on an asset-style purchase. A seller that owns an S corporation or a partnership may be able to deliver the step-up with little added cost, or may pay more tax on certain categories of gain. The difference between the two is real money, and either party may ask the other to share it through a higher price, often called a gross-up.
The practical lesson is that structure should be analyzed before a letter of intent is signed, not after. An owner who knows the value of the step-up to a buyer, and the tax cost of providing it, can decide whether to trade it for price, for certainty, or for better terms elsewhere. That analysis belongs to your tax advisors, and the earlier they are involved the more options remain.
The earnout and the 2028 target
The earnout of up to $150 million equals about 7% of the closing price, and it depends on performance targets measured in calendar 2028, more than two years after the expected closing. That timeline matters. A seller who accepts an earnout is taking part of the price as a bet on the business under new ownership, funded by a buyer that now controls the budget, the sales team, and the integration plan.
We covered contingent payments earlier this month in a post on cash plus a contingent right, and the points hold here. The metric should be defined in the agreement with examples, not just a label such as EBITDA. The buyer should commit to operate the business in a way that does not undermine the target, or at least disclose what it plans to change. Accounting policies should be fixed in advance, and the agreement should say what happens to the earnout if the buyer sells the business or merges it into another unit. Without those terms, a 2028 payment can depend on decisions the seller no longer controls.
Key Considerations
- Ask every bidder to state the price on a net basis, including the value they place on tax benefits from the structure.
- Have your tax advisor model a stock sale and an asset-style sale before you sign a letter of intent, so you know the cost of each.
- If a buyer wants a step-up, ask how much it is worth to them and whether the price reflects it.
- Treat an earnout as a separate negotiation: define the metric, fix the accounting policies, and require operating covenants.
- Convert every headline price into multiples on the same earnings figure, with and without add-backs, before you compare offers.
- Check the debt financing and closing conditions; a primarily debt-funded deal is sensitive to credit markets and approvals.
What to watch next
The first thing to watch is whether STERIS closes by its year-end target and how its revised fiscal 2027 outlook describes the debt added to its balance sheet. The second is the 2028 earnout, which will show how a large strategic buyer sets performance targets for a business it has just purchased. Smaller transactions rarely publish this much detail, so public deals like this one are a useful template for what to ask for in a private negotiation.
The Bottom Line
A $2.1 billion price became a $1.8 billion cost to the buyer once tax benefits were counted, and a potential $2.25 billion price once the earnout was added. Owners should expect their own offers to have the same layers. Ask for the net figure, understand the tax structure behind it, and treat any contingent payment as a negotiation of its own, because the headline number is only the starting point for what you will actually receive.